Upstream Bio

[Upstream Bio @UpstreamBio]

Team Upstream recently spent an afternoon out of the office for our annual summer outing. We’re grateful for the energy, collaboration and commitment this team brings every day, and for opportunities like this to connect and recharge.
#LifeAtUpstreamBio

[Upstream Bio @UpstreamBio]

On #WorldLungDay, we recognize the millions of people living with respiratory diseases, and those who help to improve respiratory health and advance care.
#RespiratoryHealth

[Upstream Bio @UpstreamBio]

September is World #SinusHealth Awareness Month and we're shining a light on #CRSwNP, a chronic inflammatory disease that affects how people breathe, smell, and experience everyday life. We're working to develop a potential new treatment option to address this disease.

[Upstream Bio @UpstreamBio]

Today at #ERS2026, we presented the results from the Phase 2 VALIANT trial of verekitug in severe asthma. Dosed every 12 weeks, verekitug reduced asthma exacerbations and improved lung function, biomarkers, and symptom control vs placebo.
https://t.co/wDT1z6wqTE
$UPB

[Upstream Bio @UpstreamBio]

Today we announced pivotal Phase 3 development plans for #verekitug in severe #asthma and #CRSwNP. Following EOP2 meetings w/FDA, we will study a 400mg quarterly regimen in one pivotal trial in each indication, on track to initiate in Q1 2027.
Learn more: https://t.co/quD55QPn1d

[Upstream Bio @UpstreamBio]

Welcome Ken Adams, joining Upstream Bio as SVP, Clinical Operations & Medical Writing and leading our Phase 3 strategy for verekitug in severe asthma & CRSwNP.

$UPB #TSLP

[Upstream Bio @UpstreamBio]

Meet Marie Sanchirico, PhD, MBA, who recently joined Upstream Bio to lead Medical Affairs. In this role, she will strengthen our engagement with physicians, investigators, and scientific experts working to improve care for people with severe inflammatory respiratory diseases

[Upstream Bio @UpstreamBio]

Today, we reported Q2 2026 financial results and continued progress for #verekitug in severe #asthma, #CRSwNP, and #COPD. We remain on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027. https://t.co/SMTjrK3Hm9

[Upstream Bio @UpstreamBio]

Today at #EAACI2026, we shared new responder analyses from the Phase 2 VIBRANT trial of verekitug in CRSwNP, showing that the majority of treated participants achieved clinically meaningful improvements in key endpoints.
https://t.co/jl0Trh7OeU
$UPB

[Upstream Bio @UpstreamBio]

Tune in today as our CEO, Rand Sutherland, MD, joins a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 10:40 a.m. ET.

Live webcast: https://t.co/UgZWkqpfkD

#verekitug $UPB

[Upstream Bio @UpstreamBio]

We’ll be at #EAACI2026 in Istanbul presenting additional analyses from the Phase 2 VIBRANT trial of verekitug in CRSwNP, featuring a responder analysis in key measures of disease.
📅 Sun 6/14 │ 15:15–16:45 local │ Room Munich
$UPB https://t.co/3Fn5loyoVd

[Upstream Bio @UpstreamBio]

Upstream Bio will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 in Miami.

📅Fireside chat │ Wed 6/10, 10:40 a.m. ET

https://t.co/DbMXbO0rmy

$UPB

[Upstream Bio @UpstreamBio]

Today at #ATS2026 Upstream Bio is presenting two posters from the Phase 2 VIBRANT trial of verekitug in CRSwNP, including data on patients with comorbid asthma. 📅 P1397 & P1398 │ Mon 5/18, 11:30 AM ET $UPB https://t.co/2FLpSU00Zv

[Upstream Bio @UpstreamBio]

Today, we reported Q1 2026 financial results and continued progress for #verekitug across severe #asthma, #CRSwNP, and #COPD.

$UPB https://t.co/yEV5bul7ED

[Upstream Bio @UpstreamBio]

We’ll be at #ATS2026 in Orlando presenting new data from the Phase 2 VIBRANT trial of verekitug in patients with CRSwNP.

📅 P1397 & P1398 | Mon 5/18, 11:30 AM ET

$UPB
https://t.co/yvdJpuAlfQ

[Upstream Bio @UpstreamBio]

Today we reported Q4 and full year 2025 financial results and outlined our Phase 3 development strategy for #verekitug. https://t.co/9u1X3vQsXn

[Upstream Bio @UpstreamBio]

Join our CEO, Rand Sutherland, MD, today March 9th at 1:40 p.m. ET for a fireside chat at the 2026 Leerink Partners Global Healthcare Conference. Tune in live or listen to the replay under the Events tab on the Investors section of our website. https://t.co/UgZWkqpfkD

[Upstream Bio @UpstreamBio]

Join our CEO, Rand Sutherland, MD, today March 4th at 9:50 a.m. ET for a fireside chat at the TD Cowen 46th Annual Healthcare Conference. Tune in live or listen to the replay under the Events tab on the Investors section of our website. Learn more here: https://t.co/O5QEc6Lv1G

[Upstream Bio @UpstreamBio]

Today at #AAAAI2026, we presented additional analyses from the VIBRANT Phase 2 trial of verekitug in chronic rhinosinusitis with nasal polyps (#CRSwNP). Read more: https://t.co/HtjHhJwK2h

[Upstream Bio @UpstreamBio]

We’ll be at #AAAAI2026 in Philadelphia presenting additional analyses from the Phase 2 VIBRANT trial of verekitug in patients with #CRSwNP. Learn more: https://t.co/xnt7deTLkD